# Celebrex In Acute Gouty Arthritis Study

> **NCT00549549** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 402 (actual)

## Conditions studied

- Arthritis, Gouty

## Interventions

- **DRUG:** Indomethacin
- **DRUG:** Celecoxib
- **DRUG:** Celecoxib
- **DRUG:** Celecoxib

## Key facts

- **NCT ID:** NCT00549549
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549549, "Celebrex In Acute Gouty Arthritis Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00549549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*